Literature DB >> 14662209

Predictors of difficulty when discontinuing postmenopausal hormone therapy.

Deborah Grady1, Bruce Ettinger, Anna N A Tosteson, Alice Pressman, Judith L Macer.   

Abstract

OBJECTIVE: To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop.
METHODS: We conducted telephone interviews with 377 randomly selected female members of the Kaiser Foundation Health Plan, aged 50-69 years, who regularly used hormone therapy for at least 1 year before July 1, 2002 and had attempted to stop between July 2002 and March 2003.
RESULTS: Of the 377 women, 280 (74%) successfully stopped and 97 (26%) resumed taking hormone therapy. The major predictor of resuming hormone therapy use was the development of troublesome withdrawal symptoms (odds ratio 8.8; 95% confidence interval 4.9, 16.0). Report of hysterectomy, hormone therapy prescribed by a nongynecologist, and perception of high risk of hip or spine fracture were independently associated with a higher likelihood of unsuccessful stopping. Women with a hysterectomy who had used hormone therapy for 10 or more years and who started hormone therapy mainly for reasons other than health promotion were more likely (P <.001) to be unsuccessful in quitting (44%) compared with those with one or two (25%) or none (9%) of these three characteristics. Most successful stoppers (71%) stopped hormone therapy abruptly, but 29% tapered off hormone therapy; there was no difference in the incidence of troublesome withdrawal symptoms or successful quitting between these two groups.
CONCLUSION: Approximately one quarter of women who try to stop report that they are unable to discontinue postmenopausal hormone therapy, primarily because they develop troublesome withdrawal symptoms. Effective approaches to reducing hormone therapy withdrawal symptoms should be a priority for future research.

Entities:  

Mesh:

Year:  2003        PMID: 14662209     DOI: 10.1016/j.obstetgynecol.2003.09.025

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial.

Authors:  Robert L Brunner; Aaron Aragaki; Vanessa Barnabei; Barbara B Cochrane; Margery Gass; Susan Hendrix; Dorothy Lane; Judith Ockene; Nancy F Woods; Shagufta Yasmeen; Marcia Stefanick
Journal:  Menopause       Date:  2010 Sep-Oct       Impact factor: 2.953

2.  Hormone therapy and fatal breast cancer.

Authors:  Sandra A Norman; Anita L Weber; A Russell Localio; Polly A Marchbanks; Giske Ursin; Brian L Strom; Linda K Weiss; Ronald T Burkman; Leslie Bernstein; Dennis M Deapen; Suzanne G Folger; Michael S Simon; Marion R Nadel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-05       Impact factor: 2.890

Review 3.  Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.

Authors:  Nancy E Avis; Sybil L Crawford; Robin Green
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

4.  Hormone therapy discontinuation: physician practices after the Women's Health Initiative.

Authors:  Katherine M Newton; Susan D Reed; Louis C Grothaus; Andrea Z La Croix; Larissa Nekhlyudov; Kelly Ehrlich; Evette J Ludman
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

5.  Factors associated with successful discontinuation of hormone therapy.

Authors:  Katherine M Newton; Susan D Reed; Larissa Nekhyludov; Louis C Grothaus; Evette J Ludman; Kelly Ehrlich; Andrea Z LaCroix
Journal:  J Womens Health (Larchmt)       Date:  2014-01-20       Impact factor: 2.681

6.  Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial.

Authors:  Sarah E Tom; Melissa L Anderson; Carol A Landis; Erin J Aiello Bowles; Nancy F Woods; Susan D Reed; Katherine M Newton; Diana S M Buist
Journal:  Menopause       Date:  2011-11       Impact factor: 2.953

7.  Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.

Authors:  Hadine Joffe; Katherine A Guthrie; Joseph Larson; Lee S Cohen; Janet S Carpenter; Andrea Z Lacroix; Ellen W Freeman
Journal:  Menopause       Date:  2013-03       Impact factor: 3.310

8.  Tapering versus cold turkey: symptoms versus successful discontinuation of menopausal hormone therapy.

Authors:  Jo-Anne Suffoletto; Rachel Hess
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

9.  The impact of comorbidities on hormone use. After the 2000 release of the Women's Health Initiative.

Authors:  Katherine M Newton; Diana S M Buist; Diana L Miglioretti; Kevin Beverly; Cynthia L Hartsfield; K Arnold Chan; Susan E Andrade; Feifei Wei; Maureen T Connelly; Larry Kessler
Journal:  J Gen Intern Med       Date:  2005-04       Impact factor: 5.128

10.  Attitudes and practices of gynecologists in Jaipur toward management of menopause.

Authors:  Shuchita Meherishi; Sunila Khandelwal; M L Swarankar; Prabhleen Kaur
Journal:  J Midlife Health       Date:  2010-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.